IMMUNITYBIO, INC. Increase (Decrease) in Due to Related Parties, Current
IMMUNITYBIO, INC. (IBRX) reported Increase (Decrease) in Due to Related Parties, Current of $2.60 million for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-05-14.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent · last filed 2021-05-14
- IMMUNITYBIO, INC. increase (decrease) in due to related parties, current for the quarter ending 2021-03-31 was $2.60M.
- IMMUNITYBIO, INC. increase (decrease) in due to related parties, current for the quarter ending 2020-12-31 was $2.29M.
- IMMUNITYBIO, INC. increase (decrease) in due to related parties, current for the quarter ending 2020-09-30 was $705.00K.
- IMMUNITYBIO, INC. increase (decrease) in due to related parties, current for the quarter ending 2020-06-30 was $2.80M.
- IMMUNITYBIO, INC. increase (decrease) in due to related parties, current for fiscal 2018 was -$685.00K, a 143.85% decline from fiscal 2017.
- IMMUNITYBIO, INC. increase (decrease) in due to related parties, current for fiscal 2017 was $1.56M, a 313.23% increase from fiscal 2016.
- IMMUNITYBIO, INC. increase (decrease) in due to related parties, current for fiscal 2016 was $378.00K, a 72.04% decline from fiscal 2015.
- IMMUNITYBIO, INC. increase (decrease) in due to related parties, current for fiscal 2015 was $1.35M.
| Period end | Increase (Decrease) in Due to Related Parties, Current 3 month | Increase (Decrease) in Due to Related Parties, Current 3 month as first filed | Increase (Decrease) in Due to Related Parties, Current 6 month | Increase (Decrease) in Due to Related Parties, Current 9 month | Increase (Decrease) in Due to Related Parties, Current 9 month as first filed | Increase (Decrease) in Due to Related Parties, Current 12 month | Increase (Decrease) in Due to Related Parties, Current 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2021-03-31 | $2.60M 10-Q · filed 2021-05-14 | $4.88M derived: sum of 2 quarters · filed 2021-05-14 | $5.59M derived: sum of 3 quarters · filed 2021-05-14 | $8.39M derived: sum of 4 quarters · filed 2021-05-14 | |||
| 2020-12-31 | $2.29M derived: 8-K/A 12 month − 10-Q 9 month · filed 2021-04-22 | $2.99M derived: sum of 2 quarters · filed 2021-04-22 | $5.79M derived: sum of 3 quarters · filed 2021-04-22 | $3.38M 8-K/A · filed 2021-04-22 | $5.03M 10-K · filed 2021-03-04 | ||
| 2020-09-30 | $705.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $3.50M derived: sum of 2 quarters · filed 2020-11-09 | $1.09M 10-Q · filed 2020-11-09 | -$450.00K derived: sum of 4 quarters · filed 2021-05-14 | |||
| 2020-06-30 | $2.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | $386.00K 10-Q · filed 2020-08-07 | -$1.16M derived: sum of 3 quarters · filed 2021-05-14 | -$1.31M derived: sum of 4 quarters · filed 2021-05-14 | |||
| 2020-03-31 | -$2.41M 10-Q · filed 2021-05-14 | $300.00K 10-Q · filed 2020-05-11 | -$3.95M derived: sum of 2 quarters · filed 2021-05-14 | -$4.11M derived: sum of 3 quarters · filed 2021-05-14 | -$4.63M derived: sum of 4 quarters · filed 2021-05-14 | ||
| 2019-12-31 | -$1.54M derived: 8-K/A 12 month − 10-Q 9 month · filed 2021-04-22 | -$1.70M derived: sum of 2 quarters · filed 2021-04-22 | -$2.22M derived: sum of 3 quarters · filed 2021-04-22 | -$2.38M 8-K/A · filed 2021-04-22 | -$1.09M 10-K · filed 2020-03-25 | ||
| 2019-09-30 | -$157.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | -$677.00K derived: sum of 2 quarters · filed 2020-11-09 | -$839.00K 10-Q · filed 2020-11-09 | -$1.34M derived: sum of 4 quarters · filed 2021-03-04 | |||
| 2019-06-30 | -$520.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | -$682.00K 10-Q · filed 2020-08-07 | -$1.19M derived: sum of 3 quarters · filed 2021-03-04 | -$859.00K derived: sum of 4 quarters · filed 2021-03-04 | |||
| 2019-03-31 | -$162.00K 10-Q · filed 2020-05-11 | -$665.00K derived: sum of 2 quarters · filed 2021-03-04 | -$339.00K derived: sum of 3 quarters · filed 2021-03-04 | -$867.00K derived: sum of 4 quarters · filed 2021-03-04 | |||
| 2018-12-31 | -$503.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | -$177.00K derived: sum of 2 quarters · filed 2021-03-04 | -$705.00K derived: sum of 3 quarters · filed 2021-03-04 | -$685.00K 10-K · filed 2021-03-04 | |||
| 2018-09-30 | $326.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | -$202.00K derived: sum of 2 quarters · filed 2019-11-05 | -$182.00K 10-Q · filed 2019-11-05 | $621.00K derived: sum of 4 quarters · filed 2020-03-25 | |||
| 2018-06-30 | -$528.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | -$508.00K 10-Q · filed 2019-08-06 | $295.00K derived: sum of 3 quarters · filed 2020-03-25 | -$375.00K derived: sum of 4 quarters · filed 2020-03-25 | |||
| 2018-03-31 | $20.00K 10-Q · filed 2019-05-08 | $823.00K derived: sum of 2 quarters · filed 2020-03-25 | $153.00K derived: sum of 3 quarters · filed 2020-03-25 | $268.00K derived: sum of 4 quarters · filed 2020-03-25 | |||
| 2017-12-31 | $803.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-25 | $133.00K derived: sum of 2 quarters · filed 2020-03-25 | $248.00K derived: sum of 3 quarters · filed 2020-03-25 | $1.56M 10-K · filed 2020-03-25 | |||
| 2017-09-30 | -$670.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | -$555.00K derived: sum of 2 quarters · filed 2018-11-07 | $759.00K 10-Q · filed 2018-11-07 | $636.00K derived: sum of 4 quarters · filed 2019-03-13 | |||
| 2017-06-30 | $115.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-06 | $1.43M 10-Q · filed 2018-08-06 | $1.31M derived: sum of 3 quarters · filed 2019-03-13 | $1.43M derived: sum of 4 quarters · filed 2019-03-13 | |||
| 2017-03-31 | $1.31M 10-Q · filed 2018-05-07 | $1.19M derived: sum of 2 quarters · filed 2019-03-13 | $1.32M derived: sum of 3 quarters · filed 2019-03-13 | $1.37M derived: sum of 4 quarters · filed 2019-03-13 | |||
| 2016-12-31 | -$123.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-13 | $3.00K derived: sum of 2 quarters · filed 2019-03-13 | $56.00K derived: sum of 3 quarters · filed 2019-03-13 | $378.00K 10-K · filed 2019-03-13 | |||
| 2016-09-30 | $126.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $179.00K derived: sum of 2 quarters · filed 2017-11-07 | $501.00K 10-Q · filed 2017-11-07 | $628.00K derived: sum of 4 quarters · filed 2018-03-12 | |||
| 2016-06-30 | $53.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | $375.00K 10-Q · filed 2017-08-07 | $502.00K derived: sum of 3 quarters · filed 2018-03-12 | ||||
| 2016-03-31 | $322.00K 10-Q · filed 2017-05-08 | $449.00K derived: sum of 2 quarters · filed 2018-03-12 | |||||
| 2015-12-31 | $127.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $1.35M 10-K · filed 2018-03-12 | |||||
| 2015-09-30 | $1.23M 10-Q · filed 2016-11-10 | $610.00K 10-Q · filed 2015-11-12 | |||||
| 2014-12-31 | $0.00 10-K · filed 2017-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |